Shares of Pharming surged this morning after the Dutch biotech announced that it had won the FDA's orphan drug designation for recombinant human fibrinogen (rhFIB) for the treatment of bleeding in patients deficient in fibrinogen. Pharming is one of the leading developers of transgenic therapies, which uses animals as a low-cost production system.
"Pharming's development strategy for rhFIB will utilize the successful model of recombinant blood clotting proteins to control bleeding for various genetic and acquired deficiencies," says CEO Dr. Francis Pinto. "As Rhucin nears its first market authorization, rhFIB represents another avenue of growth for Pharming and demonstrates our strength in developing therapeutic recombinant proteins for unmet medical needs."
- check out the release
Pharming says it's closing in on Rhucin approval. Report
Pharming inks creative drug partnering pact. Report
Pharming wins fast track review, shares jump. Report
Pharming gets orphan status for transgenic therapy. Report